Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishal Bhatnagar

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Journal of Geriatric Oncology|December 17, 2023
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailtyMeena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 20, 2023
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple MyelomaMeena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Blood Advances|February 3, 2022
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trialsBindu Kanapuru, Laura L Fernandes, Lola A Fashoyin-Aje, et al.
Cancer|December 4, 2014
Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center studyVishal Bhatnagar, Yin Wu, Olga G Goloubeva, et al.
Nature Reviews. Drug Discovery|February 28, 2023
The opportunity for greater patient and public involvement and engagement in drug development and regulationOlalekan Lee Aiyegbusi, Samantha Cruz Rivera, Kathy Oliver, et al.
The Oncologist|September 15, 2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior TherapyVishal Bhatnagar, Nicole J Gormley, Lola Luo, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting SeriesGita Thanarajasingam, Ajay Major, Vishal Bhatnagar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell CarcinomaJaleh Fallah, Brian L Heiss, Hee-Koung Joeng, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 20, 2024
What facets of physical function are most important to adults diagnosed with cancer?Theresa Coles, Kate Plyler, Alexy Hernandez, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 20, 2024
Facets of physical function assessed by patient-reported outcome measures in oncology researchTheresa Coles, Rebecca Fillipo, Kate Plyler, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Journal of Geriatric Oncology|December 17, 2023
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailtyMeena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 20, 2023
Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple MyelomaMeena N Murugappan, Bellinda L King-Kallimanis, Vishal Bhatnagar, et al.
Blood Advances|February 3, 2022
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trialsBindu Kanapuru, Laura L Fernandes, Lola A Fashoyin-Aje, et al.
Cancer|December 4, 2014
Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center studyVishal Bhatnagar, Yin Wu, Olga G Goloubeva, et al.
Nature Reviews. Drug Discovery|February 28, 2023
The opportunity for greater patient and public involvement and engagement in drug development and regulationOlalekan Lee Aiyegbusi, Samantha Cruz Rivera, Kathy Oliver, et al.
The Oncologist|September 15, 2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior TherapyVishal Bhatnagar, Nicole J Gormley, Lola Luo, et al.
The Lancet. Haematology|May 30, 2025
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting SeriesGita Thanarajasingam, Ajay Major, Vishal Bhatnagar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell CarcinomaJaleh Fallah, Brian L Heiss, Hee-Koung Joeng, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 20, 2024
What facets of physical function are most important to adults diagnosed with cancer?Theresa Coles, Kate Plyler, Alexy Hernandez, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 20, 2024
Facets of physical function assessed by patient-reported outcome measures in oncology researchTheresa Coles, Rebecca Fillipo, Kate Plyler, et al.
Pageof 8